| 
			
			 The testimony came at the start of the trial in federal court in 
			Concord, New Hampshire, of Christopher Clough, a physician assistant 
			who prosecutors say accepted nearly $50,000 from Insys in exchange 
			for prescribing its powerful opioid pain drug, Subsys. 
 The trial could provide a glimpse into some of the evidence 
			prosecutors will use in next month's trial of six former Insys 
			executives and managers, including John Kapoor, a onetime 
			billionaire who was the company's founder and chairman.
 
 Prosecutors say they conspired to pay kickbacks to doctors and 
			others like Clough by paying them fees to participate in "sham" 
			speaker programs ostensibly meant to educate medical professionals 
			about the drug. Clough, 45, has pleaded not guilty.
 
 
			
			 
			Among Wednesday's witnesses was Natalie Babich, the former Insys 
			sales representative and wife of former Insys Chief Executive 
			Michael Babich. The former CEO faces trial along with Kapoor. Both 
			men have pleaded not guilty.
 
 Natalie Babich testified pursuant to a cooperation agreement after 
			pleading guilty to conspiring to pay kickbacks in 2017.
 
 Babich said she had been seeking a "big fish" to write Subsys 
			prescriptions when she met Clough in 2013. Immediately after he 
			wrote his first prescription, she asked him if he would want to 
			become a paid speaker, Babich testified.
 
			
            [to top of second column] | 
 
			"Right away he just said to me, 'sure, I'll be a speaker, but I want 
			doctor money'," she said.
 Babich said she made clear to Clough that the speaker programs were 
			a reward for prescribing Subsys, an under-the-tongue spray meant for 
			cancer patients that contains fentanyl, an opioid 100 times stronger 
			than morphine.
 
			Clough frequently got paid for being a speaker at dinners with her 
			with no attendees, Babich said.
 Patrick Richard, Clough's lawyer, in his opening statement said his 
			client had no idea Insys was trying to bribe medical practitioners 
			like himself, and that he prescribed Subsys to patients at his pain 
			clinic believing it was a good treatment.
 
 "This isn't a case about individual greed but corporate greed," he 
			said.
 
 In August, Insys said it had agreed to settle a related U.S. Justice 
			Department probe for at least $150 million. It resolved a probe by 
			New Hampshire's attorney general focused on payments to Clough for 
			$3.4 million in 2017.
 
 (Reporting by Nate Raymond in Boston; Editing by Matthew Lewis and 
			Bill Berkrot)
 
			[© 2018 Thomson Reuters. All rights 
				reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |